Results 151 to 160 of about 31,062 (287)

Differences in biomarkers and molecular pathways according to age for patients with HFrEF [PDF]

, 2020
João Pedro Ferreira, Wouter Ouwerkerk, Bernadet T. Santema, Dirk J. van Veldhuisen, Chim C. Lang, Leong L. Ng, Stefan D. Anker, Kenneth Dickstein, Marco Metra, John G.F. Cleland, Samani J Nilesh, Gerasimos Filippatos, Joseph Pierre Aboumsallem, Rudolf A. de Boer, Sylwia M. Figarska, Iziah E Sama, Adriaan A. Voors, Faı̈ez Zannad   +17 more
openalex   +1 more source

Update on Percutaneous Treatment for HFrEF: A Great Armamentarium for a Poor Ventricular Function [PDF]

, 2023
Antonio Sisinni, Matteo Casenghi, Antonio Popolo Rubbio, Andrea Berni, Francesco Bedogni, Emanuele Barbato   +5 more
openalex   +1 more source

Circulating oxylipins predict mortality in heart failure with preserved ejection fraction

ESC Heart Failure, EarlyView.
A targeted LC–MS lipidomics approach identified arterial 15‐keto PGF2a as associated with 5‐year mortality in 90 patients with HFpEF. Abstract Aims Heart failure with preserved ejection fraction (HFpEF) poses significant diagnostic, prognostic and therapeutic challenges, with high morbidity and mortality rates.
Vaishnavi Aradhyula, Sareeta Manandhar, Alborz Sherafati, Alex Kloster, Anas Fares, Prabhatchandra Dube, Pamela S. Brewster, George V. Moukarbel, Krishna Rao Maddipati, Steven T. Haller, David J. Kennedy, Rajesh Gupta, Samer J. Khouri   +12 more
wiley   +1 more source

Mapping of current practices of palliative care for patients with heart failure throughout Europe: A scoping review

ESC Heart Failure, EarlyView.
Abstract Heart failure (HF) is a growing health and societal challenge in Europe, due to an increasingly elderly, frail and multimorbid population. Many patients with HF experience a high burden of complex and multidimensional symptoms leading to a reduced quality of life and significant socioeconomic impact. Despite proven benefits, the integration of
Tania Pastrana, Matthew Grant, Paula Hidalgo Andrade, Daniele Marelli, Klaus Witte, Geert‐Jan Geersing, Carla Ripamonti, Roman Rolke, Marco Metra, Matteo Pagnesi, Everlien De Graaf, Cosimo Chelazzi, on behalf of the RAPHAEL consortium   +12 more
wiley   +1 more source

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF [PDF]

, 2021
Mei Qiu, Liang‐Liang Ding, Ze‐Lin Zhan, Hairong Zhou   +3 more
openalex   +1 more source

Worsening versus advanced heart failure: Management and challenges

ESC Heart Failure, EarlyView.
Clinical feature, circulating biomarkers and therapeutic management of patients with WHF versus AdvHF. Abbreviations: AdvHF, advanced heart failure; HF, heart failure; HTx, heart transplant; GDMT, guideline‐directed medical therapy; MCS, mechanical circulatory support; NYHA, New York Heart Association; WHF, worsening heart failure.
Alberto Palazzuoli, Marco Giuseppe Del Buono, Giulia La Vecchia, Stephen J. Greene, Andrew P. Ambrosy, Ovidiu Chioncel, Finn Gustafsson, Selim R. Krim, Carl J. Lavie, Marianna Adamo, Tuvia Ben Gal, Oliviana Geavlete, Laura Antohi, Giuseppe Rosano, Sean Collins, Filippo Crea   +15 more
wiley   +1 more source

The loss of left atrial contractile function predicts a worse outcome in HFrEF patients [PDF]

, 2023
Giulia Elena Mandoli, Maria Concetta Pastore, Giovanni Benfari, Martina Setti, Luca Maritan, Enrico Emilio Diviggiano, Flavio D’Ascenzi, Marta Focardi, Luna Cavigli, Serafina Valente, Matteo Cameli   +10 more
openalex   +1 more source

Új lehetőség a szisztolés szívelégtelenség (HFrEF) kezelésében: omecamtiv-mecarbil [PDF]

, 2021
Arnold Péter Ráduly, Attila Tóth, Zoltán Papp, Attila Borbély   +3 more
openalex   +1 more source

Use of artificial intelligence for detecting left ventricular dysfunction and predicting incident heart failure risk

ESC Heart Failure, EarlyView.
Abstract Effective medications are available for the prevention of heart failure (HF). While their use is indicated in patients with risk factors, engagement and adherence among ‘at risk’ individuals is challenging, as it is with atherosclerotic heart disease prevention.
Anna Węgrzyn‐Witek, Monika Przewlocka‐Kosmala, Wojciech Kosmala, Thomas H. Marwick   +3 more
wiley   +1 more source

SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI [PDF]

, 2023
Yulin Yang, Xiaolin Wang, Yongchao Wang, Hao Xu, Li J   +4 more
openalex   +1 more source